Phone: +48 601 237 553


In the year 1980 the Division of Immunotherapy was founded in the K. Dłuski Hospital (built in XIX century). Professor Andrzej Lange, MD organized and headed the division as well as the Laboratory of Clinical Immunology in the Institute of Immunology and Exp Therapy of the Polish Academy of Sciences in Wrocław  In rather difficult environment we organized the ward for marrow transplanted patients and hematology division. The first high-dose chemotherapy secured by autologous transplantation (autoHSCT) was performed in 1987. Altogether, 1337 HSCT were performed and 30 years observation showed the survival of 40% to 39% in auto and allo HSCT. Cytopheretic unit provides the ward with peripheral blood products for transplantation and also offers therapeutic cytophoresis. There is about 7000 admissions per year including leukemias and lymphomas and a variety of blood dyscrasias. The laboratory is well suited for cytometric and genetic work. The survival curves of patients with leukemias varied at 5 years post diagnosis time point from 52% (favorable) to 25 % (unfavorable). Targeted therapy is offered and the effect is monitored if novel published. Immunology division is leading in European in providing for 35 years immunoglobulins to the patients. 

Our study on the biology of the marrow cells brought our interest to the field of regenerative medicine.  It was in the year  2003 when the first revascularization attempt was undertaken in the patients with critical limb ischemia. The marrow derived cells were enriched in  progenitor cells with the use of leukophoresis and injected intra-muscularly to the ischemic leg. The distance of claudication improved, pain was diminished and the ulceration healed in 60% of patients letting those affected  to escape from amputation. In addition the subpopulation of progenitor cells involved in the positive effect was identified and it appeared that it is different from that  active in regeneration of joints. In the latter group also marrow derived cells are injected intra-articular with appreciable effect in majority of the patients. Even more spectacular effect is seen in regeneration of bones with avascular necrosis. Marrow derived cells given  to the affected areas regenerate vasculature  improving the function.

LSCCT worked out the novel approach to regenerate the immune system raddled fighting leukemia. To regenerate the immune system in leukemic patients relapsing post-transplant the fresh donor cells are injected directly to the marrow activity mounting the vigorous response against leukemia. This was documented following the fate of the patients under this treatment and

also evaluating the immune system with the use of next generation sequencing.  Having in use the optimal genetic technology we can offer the patients a complex treatment hitting  the cancer cells.

In the year 1994 in the LSCCT the National Marrow Donor Registry was organized which is busy not only in recruiting the donors but also in searching the world-wide registry for a  candidate donor matching the best donor wherever might be.  More than 1250 donors were identified in Polish and foreign registries what effected in transplantations performed. Similarly 55 donors from the world-wide registries were identified to use their hematopoietic tissue for transplantation in our institution.

We are proud to have pioneered:

  • the use of high-dose chemotherapy with autolHSCT in lung cancer patients (1987), the approach evolving further to triple transplantation performed consecutively. A study based on international cooperation proved to be effective in a proportion of patients with this deadly disease.
  • the use of high-dose chemotherapy with autologous transplantation in ovarian cancer patients. In addition, the effect of immunologic surveillance on this cancer was documented in the laboratory on a clinical observation basis (1990).
  • the use of mobilized peripheral blood cells in the allogeneic setting. This activity was preceded by our discovery of the presence in blood of myeloid precursors (1986) under control of the immune system, precluding spontaneous differentiation.
  • counter-flow centrifugation employing technique was successfully used in haploidentical transplantations, letting the transplantologist modify the composition of peripheral blood progenitor cells to secure the take and to diminish the risk of GvHD.
  • the use of reduced intensity conditioning lacking irradiation in allogeneic transplantation in Fanconi’s anaemia patients, which has resulted in +20 years of uncomplicated survival in majority of patients;
  • the use of transplantation in children with the Cernunnos syndrome;

Our activity extends to 22 countries providing haematological treatment and matching donors for Polish recipients and vice-versa. Marrow transplantation was performed in a number of patients from Lithuania and Ukraine. The potential of innovative technologies was often ignored, being mis-labelled as scientific adventuring, rather than patient-orientated lifesaving activity. Our work published in 260 peer-reviewed articles with more than 1900 quotations.